Cesium Removal from Human Blood by Poly(ethylene glycol)-Decorated Prussian Blue Magnetic Nanoparticles

Amifostine-loaded Prussian blue nanoparticles for simultaneous efficient radioprotection and deep decorporation of radiocesium

Radiocesium is highly water-soluble and easily accumulates in agricultural products and seafood. Ingestion of radiocesium results in internal irradiation, significantly increasing the risk of tissue and organ damage as well as carcinogenesis. In this paper, we develop a strategy for simultaneous radioprotection and decorporation of radiocesium by amifostine-loaded Prussian blue (Am@PB) nanoparticles. The nanoparticles are prepared through chemical coordination between amine/phosphate groups of amifostine and Fe (II)/Fe (III) sites of Prussian blue (PB). Am@PB nanoparticles mitigate radiation-induced damage to peripheral blood cells and organs, improving the survival rate of irradiated mice. This is due to the synergistic effects of the nano-enzymatic activity of PB component and the high reducibility of sulfhydryl groups generated through amifostine hydrolysis by alkaline phosphatase. Furthermore, the deep excretion of cesium is achieved via feces along the metabolic pathway of Am@PB, leading to an enhanced decorporation efficiency of over 50 % compared to orally administered commercial PB. This work provides a design strategy for efficient radioprotective decorporation agents with potential applications in the treatment of internal radiocesium contamination.

Research progress on the synthesis, performance regulation, and applications of Prussian blue nanozymes

Nanocatalytic medicine offers a novel solution to address the issues of low efficacy, potential side effects, and the development of drug resistance associated with traditional therapies. Therefore, developing highly efficient and durable nanozymes is of great significance for treating diseases related to oxidative stress. In recent years, prussian blue nanoparticles (PBNPs) have been demonstrated to possess multiple enzyme-like catalytic activities and are thus referred to as prussian blue nanozymes (PBNZs). Their excellent biocompatibility and biodegradability make PBNZs promising candidates as biomedical materials. Due to their remarkable catalytic activities, PBNZs have shown great potential in various biomedical applications, such as heavy metal detoxification, antioxidative damage, and anticancer therapies. This paper systematically summarizes the Synthetic strategies of PBNZs, analyzes the regulatory factors of their catalytic performance, and highlights the corresponding modulation methods. Furthermore, the biomedical applications of PBNZs are also reviewed. This study aims to provide researchers with insights and inspirations for the design and preparation of high-performance PBNZs.

Decorporation dilemma: Interplay of prussian blue and potassium iodide in radioactive contamination

The expansion of the nuclear industry has led to various radioactive effluents, originating from routine operations or catastrophic incidents such as those at Three Mile Island (USA), Chernobyl (Ukraine), and Fukushima (Japan). Research conducted after these events emphasizes Cesium-137 (137Cs) and iodine 131 (131I) as major contributors to harmful airborne dispersion and fallout. These isotopes infiltrate the human body via inhalation, ingestion, or wounds, posing significant health risks. Understanding contamination mechanisms and devising effective countermeasures are crucial in mitigating nuclear incident consequences. We propose that concurrent administration of Pru-Decorp™/Pru-Decorp-MG and potassium iodide (KI) could synergistically reduce the levels of 137Cs and block uptake of 131I, respectively, in nuclear incident scenarios. Pru-Decorp™ capsules contain insoluble ferric hexacyanoferrate(II) and are equivalent to USFDA-approved Radiogardase®-Cs, offering radiation exposure mitigation for Cs and Tl contamination. Pru-Decorp-MG capsules consist of insoluble PB and magnesium hydroxide, serving as a prophylactic measure to reduce the risk of internal Cs and Tl contamination for rescue responders. Pru-Decorp™/Pru-Decorp-MG binds Cs/Tl ions in the gastrointestinal tract, hindering absorption and promoting excretion, while KI saturates the thyroid gland with stable iodine, decreasing the uptake of radioactive iodine isotopes. Our hypothesis is supported by studies demonstrating the effectiveness of combination therapies, such as calcium alginate, iron(III) ferrocyanide, and KI, in decreasing the retention of radioisotopes in vital organs. To test this hypothesis, we propose a comprehensive research plan, including in vitro studies simulating gastrointestinal conditions, animal studies to evaluate the efficacy of both drugs simultaneously, and safety clinical trials comparing Pru-Decorp™/Pru-Decorp-MG alone, KI alone, and their combination. Expected outcomes include insights into the synergistic effects of Pru-Decorp™/Pru-Decorp-MG and KI, guiding the development of optimized treatment protocols for simultaneous administration during radioactive contamination incidents. This research aims to address significant critical gaps in nuclear incident preparedness by providing evidence-based recommendations for concurrent antidote use in scenarios involving multiple isotope contamination. Ultimately, this will enhance public health and safety during nuclear emergencies.

DNA-modified Prussian blue nanozymes for enhanced electrochemical biosensing

Prussian blue nanoparticles exhibit the potential to be employed in bioanalytical applications due to their robust stability, peroxidase-like catalytic functionality, straightforward synthesis, and biocompatibility. An efficient approach is presented for the synthesis of nucleic acid-modified Prussian blue nanoparticles (DNA-PBNPs), utilizing nanoparticle porosity to adsorb nucleic acids (polyT). This strategic adsorption leads to the exposure of nucleic acid sequences on the particle surface while retaining catalytic activity. DNA-PBNPs further couple with functional nucleic acid sequences and aptamers through complementary base pairing to act as transducers in biosensors and amplify signal acquisition. Subsequently, we integrated a copper ion-dependent DNAzyme (Cu2+-DNAzyme) and a vascular endothelial growth factor aptamer (VEGF aptamer) onto screen-printed electrodes to serve as recognition elements for analytes. Significantly, our approach leverages DNA-PBNPs as a superior alternative to traditional enzyme-linked antibodies in electrochemical biosensors, thereby enhancing both the efficiency and adaptability of these devices. Our study conclusively demonstrates the application of DNA-PBNPs in two different biosensing paradigms: the sensitive detection of copper ions and vascular endothelial growth factor (VEGF). These results indicate the promising potential of DNA-modified Prussian blue nanoparticles in advancing bioanalytical sensing technologies.

Nanosized Prussian blue and its analogs for bioimaging and cancer theranostics

Prussian blue (PB) nanoparticles (NPs) and Prussian blue analogs (PBAs) can form metal-organic frameworks through the programmable coordination of ferrous ions with cyanide. PB and PBAs represent a burgeoning class of hybrid functional nano-systems with a wide-ranging application spectrum encompassing biomedicine, cancer diagnosis, and therapy. A comprehensive overview of recent advancements is crucial for gaining insights for future research. In this context, we reviewed the synthesis techniques and surface modification strategies employed to tailor the dimensions, morphology, and attributes of PB NPs. Subsequently, we explored advanced biomedical utilities of PB NPs, encompassing photoacoustic imaging, magnetic resonance imaging, ultrasound (US) imaging, and multimodal imaging. In particular, the application of PB NPs-mediated photothermal therapy, photodynamic therapy, and chemodynamic therapy to cancer treatment was reviewed. Based on the literature, we envision an evolving trajectory wherein the future of Prussian blue-driven biological applications converge into an integrated theranostic platform, seamlessly amalgamating bioimaging and cancer therapy. STATEMENT OF SIGNIFICANCE: Prussian blue, an FDA-approved coordinative pigment with a centuries-long legacy, has paved the way for Prussian blue nanoparticles (PB NPs), renowned for their remarkable biocompatibility and biosafety. These PB NPs have found their niche in biomedicine, playing crucial roles in both diagnostics and therapeutic applications. The comprehensive review goes beyond PB NP-based cancer therapy. Alongside in-depth coverage of PB NP synthesis and surface modifications, the review delves into their cutting-edge applications in the realm of biomedical imaging, encompassing techniques such as photoacoustic imaging, magnetic resonance imaging, ultrasound imaging, and multimodal imaging.

A Prussian blue analog as a decorporation agent for the simultaneous removal of cesium and reactive oxygen species

Radioactive cesium (Cs) is a significant concern due to its role as a major byproduct of nuclear fission and its potential for radioactive contamination. Internal contamination with radioactive Cs is characterized by immoderate production of reactive oxygen species (ROS), resulting in severe radiation damage. Therefore, the development of therapeutic strategies should focus on enhancing the excretion of radioactive Cs and reducing radiation-induced oxidative damage. However, current therapeutic drugs like Prussian blue (PB) have limited efficacy in addressing these issues. In this study, we present Cu3[Fe(CN)6]2 (CuFe) nanoparticles, a Prussian blue analog (PBA), which can not only efficiently sequester Cs but also exhibit resistance against radiation damage. The results of the adsorption studies demonstrate that CuFe outperforms PB in terms of adsorption performance. Further mechanistic investigations indicate that the increased adsorption capacity of CuFe may be attributed to the presence of additional defects resulting from the [Fe(CN)6] missing linkers. Moreover, CuFe mimics the functions of catalase (CAT) and superoxide dismutase (SOD) by effectively eliminating O2˙- and H2O2 while scavenging ˙OH, thereby mitigating ROS induced by radiative Cs. Importantly, in vivo study confirms the efficient Cs decorporation capability of CuFe. The fecal cumulative excretion rate of CuFe reaches 69.5%, which is 1.45 times higher than that of PB (48.8%). These findings demonstrate that CuFe exhibits excellent Cs removal performance and ROS scavenging ability, making it an attractive candidate for the treatment of Cs contamination.

The latest research trends in the removal of cesium from radioactive wastewater: A review based on data-driven and visual analysis

The widespread adoption of nuclear energy has increased the amount of radioactive cesium (Cs) that is discharged into waste streams, which can have environmental risks. In this paper, we provide a comprehensive summary of current advances in aqueous Cs removal by employing a bibliometric analysis. We collected 1580 articles related to aqueous Cs treatment that were published on the Web of Science database between 2012 and 2022. By applying bibliometric analysis combined with network analysis, we revealed the research distribution, knowledge base, research hotspots, and cutting-edge technologies in the field of aqueous Cs removal. Our findings indicate that China, Japan, and South Korea are the most productive countries with respect to Cs removal research. In addition, both historic events and environmental threats might have contributed to research in Asian countries having a higher focus on Cs removal as well as strong international cooperation between Asian countries. A detailed keyword analysis reveals the main knowledge base for aqueous Cs removal and highlights the potential of the adsorption-based method for treating Cs contamination. Furthermore, the results reveal that exploration of functional materials is a popular research topic in the field of Cs removal. Since 2012, novel materials, including Prussian blue, graphene oxide, hydrogel and nanocomposites, have been widely investigated because of their high capacity for Cs removal. On the basis of the detailed information, we report the latest research trends on aqueous Cs removal, and propose future research directions and describe the challenges related to effective Cs treatment. This scientometric review provides insights into current research hotspots and cutting-edge trends in addition to contributing to the development of this crucial research field.

Prussian Blue: A Safe Pigment with Zeolitic-Like Activity

Prussian blue (PB) and PB analogues (PBA) are coordination network materials that present important similarities with zeolites concretely with their ability of adsorbing cations. Depending on the conditions of preparation, which is cheap and easy, PB can be classified into soluble PB and insoluble PB. The zeolitic-like properties are mainly inherent to insoluble form. This form presents some defects in its cubic lattice resulting in an open structure. The vacancies make PB capable of taking up and trapping ions or molecules into the lattice. Important adsorption characteristics of PB are a high specific area (370 m2 g-1 determined according the BET theory), uniform pore diameter, and large pore width. PB has numerous applications in many scientific and technological fields. PB are assembled into nanoparticles that, due to their biosafety and biocompatibility, can be used for biomedical applications. PB and PBA have been shown to be excellent sorbents of radioactive cesium and radioactive and nonradioactive thallium. Other cations adsorbed by PB are K+, Na+, NH4+, and some divalent cations. PB can also capture gaseous molecules, hydrocarbons, and even luminescent molecules such as 2-aminoanthracene. As the main adsorptive application of PB is the selective removal of cations from the environment, it is important to easily separate the sorbent of the purified solution. To facilitate this, PB is encapsulated into a polymer or coats a support, sometimes magnetic particles. Finally, is remarkable to point out that PB can be recycled and the adsorbed material can be recovered.

Dual Effect of Prussian Blue Nanoparticles on Aβ40 Aggregation: β-Sheet Fibril Reduction and Copper Dyshomeostasis Regulation

Alzheimer's disease (AD), affecting almost 50 million individuals worldwide, is currently the first cause of dementia. Despite the tremendous research efforts in the last decade, only four supportive or palliative drugs, namely, acetylcholinesterase (AChE) inhibitors donepezil, galantamine, and rivastigmine and the glutamate NMDA receptor antagonist memantine, are currently available. New therapeutic strategies are becoming prominent, such as the direct inhibition of amyloid formation or the regulation of metal homeostasis. In the present report, the potential use of Prussian blue (PB), a drug that is in the World Health Organization Model List of Essential Medicines, in AD treatment is demonstrated. Both in vitro and in cellulo studies indeed suggest that PB nanoparticles (PBNPs) are capable of reducing the formation of typical amyloid-β fibers (detected by thioflavin T fluorescence) and restoring the usual amyloid fibrillation pathway via chelation/sequestration of copper, which is found in high concentrations in senile plaques.

Prussian blue nanoparticles: synthesis, surface modification, and biomedical applications

Prussian blue nanoparticles (PBNPs) are a nanomaterial that presents unique properties and an excellent biocompatibility. They can be synthesized in mild conditions and can be derivatized with polymers and/or biomolecules. PBNPs are used in biomedicine as therapy and diagnostic agents. In biomedical imaging, PBNPs constitute contrast agents in photoacoustic and magnetic resonance imaging (MRI). They are a good adsorbent to be used as antidotes for poisoning with cesium and/or thallium ions. Moreover, the ability to convert energy into heat makes them useful photothermal agents (PAs) in photothermal therapy (PTT) or as nonantibiotic substances with antibacterial properties. Finally, PBNPs can be both reduced to Prussian white and oxidized to Prussian green. A large window of redox potential exists between reduction and oxidation, which result in the enzyme-like characteristics of these NPs.

Facile Synthesis of Novel Prussian Blue-Lipid Nanocomplexes

Prussian blue (PB) is known for its multiple applications ranging from fine arts to therapeutics. More recently, PB nanoparticles have been pointed to as appealing photothermal agents (PA) when irradiated with wavelengths corresponding to the biological windows, namely regions located in the near infrared (NIR) zone. In addition, the combination of PB with other components such as phospholipids boosts their therapeutical potential by facilitating, for instance, the incorporation of drugs becoming suitable drug delivery systems. The novelty of the research relies on the synthesis procedure and characterization of hybrid lipid-PB nanoparticles with a high yield in a friendly environment suitable for photothermal therapy. This goal was achieved by first obtaining insoluble PB coated with oleylamine (OA) to facilitate its combination with lipids. The resulting lipid-PB complex showed a monomodal distribution of sizes with an overall size of around 100 nm and a polydispersity index of about 0.200. It highlights one critical step in the synthesis procedure that is the shaking time of the mixture of PB-OA nanoparticles with the lipid, which was found to be 48 h. This time assured homogeneous preparation without the need of further separation stages. Samples were stable for more than three months under several storage conditions.

Synthesis of uniform Prussian blue nanoparticles by a polyol process using a polyethylene glycol aqueous solution

A polyol process was applied to the synthesis of Prussian blue nanoparticles that have a narrow size distribution. Potassium hexacyanidoferrate(iii) and iron(iii) nitrate aqueous solutions were introduced into a 50% polyethylene glycol (PEG) aqueous solution under magnetic stirring at 50 °C and reacted for 48 h. The shape of the so-obtained particles was cubic with somewhat rounded edges and the mean size was 70 nm. In the formation process, nanoparticles of Prussian green, which is a partially oxidized state of Prussian blue, were firstly generated via reduction of the precursors by PEG molecules. The Prussian green nanoparticles were then reduced subsequently to Prussian blue nanoparticles. Rate constants for both the reduction steps have been estimated using the time evolution of absorbance.

A polyol process using PEG aqueous solution is applicable to synthesize uniform Prussian blue nanoparticles.

Progress in Applications of Prussian Blue Nanoparticles in Biomedicine

Prussian blue nanoparticles (PBNPs) with favorable biocompatibility and unique properties have captured the attention of extensive biomedical researchers. A great progress is made in the application of PBNPs as therapy and diagnostics agents in biomedicine. This review begins with the recent synthetic strategies of PBNPs and the regulatory approaches for their size, shape, and uniformity. Then, according to the different properties of PBNPs, their application in biomedicine is summarized in detail. With modifiable features, PBNPs can be used as drug carriers to improve the therapeutic efficacy. Moreover, the exchangeable protons and adsorbability enable PBNPs to decontaminate the radioactive ions from the body. For biomedical imaging, photoacoustic and magnetic resonance imaging based on PBNPs are summarized, as well as the strategies to improve the diagnostic effectiveness. The applications related to the photothermal effects and nanoenzyme activities of PBNPs are described. The challenges and critical factors for the clinical translation of PBNPs as multifunctional theranostic agents are also discussed. Finally, the future prospects for the application of PBNPs are considered. The aim of this review is to provide a better understanding and key consideration for rational design of this increasingly important new paradigm of PBNPs as theranostics.